CLLS
CellectisANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
Current thesis
The bull case is that June RMAT designation and the final Phase 1 BALLI-01 dataset improved the regulatory and clinical setup ahead of the pivotal Phase 2 interim analysis, while the May 11 company update also pointed to cash runway into Q4 2027, reducing immediate financing pressure. [#IR-2026-06-09] [#IR-2026-06-11] [#IR-2026-05-11]
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite.
What can break
BALLI-01 remains the dominant binary risk, and a disappointing pivotal Phase 2 interim analysis in Q4 2026 would likely outweigh the June RMAT-related optimism.
Momentum
95
Value
41
Sentiment
70
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $3.40 · Bull $5.20 · Bear $1.80
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-07-13 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $7.49
Why
Momentum95 · Δ7d -
Value41 · Δ7d -0.1
Sentiment70 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
95
26% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
0.0
Sentiment
70
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade A. Momentum 95.1 / Value 41.1 / Sentiment 70.3
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$188.86M
Beta
2.83
Shares Out
72.33M
P/E (TTM) · Derived
-3.9
P/S (TTM)
4.01
P/FCF (TTM)
17.30
Rev YoY
-45.6%
EPS YoY
-2.0%
Gross Margin
+71.1%
Op Margin
-32.0%
Net Debt
-$88.76M
Current Ratio
1.52
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology